Boehringer eyes third quarter FDA verdict for oral HER2 drug

The FDA has started a priority review of Boehringer Ingelheim's small-molecule HER2 inhibitor zongertinib as a treatment for a form of lung cancer, setting up a decision later this year and giving it a lead over a rival programme at Bayer.